Adding Auris Medical (EARS) $3.50 to Biotech Watch List.
Auris Medical soared 590% in one Week on Covid Related News on December 1st, 2020.
LIFT OFF $0.94 to $6.60
LIVE QUOTE
While we were waiting for...
GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.
ILLUSTRATION 3 |MISSION AND STRATEGY
Our mission: One is to innovate. The other one is to differentiate. The other one is to accelerate and finally...
Amazing Sales of Paxlovid (CBS News).
"These medicines have a sweet spot. If the day you get diagnosed COVID you say 'forget it, I'll be fine,' and then several days...
Tax Loss Selling Bargain? Adding Aditxt (ADTX).
Adding Aditxt (ADTX) to the upcoming "2022 Biotech 6-Pack, Stocks We Expect to Double" Watch List.
We're sitting in a hotel room in Chicago minding...
Adding Brainstorm Therapeutics (BCLI) $4.59 to CoronaVirus Watchlist.
This is a company exploring the use of stem cells for a number of ailments. The lead program is (or was) for ALS or...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous...
GeoVax (GOVX) Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen...
https://youtu.be/4LffUyg6yE8?si=G8_kZMce8yHGCxKp
GEO-CM04S1 Offers Solution to Overcome HHS-Cited mRNA Deficiencies - Potentially Offering Broader, More Durable Protection
ATLANTA, GA - August 7, 2025 (NEWMEDIAWIRE) - GeoVax Labs,...
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021 @$1.80Cash has Risen From $3.3 Million...
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that the amended protocol is still under...
Revive Therapeutics Updates, on Phase III Clinical Trial!
Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.."
Revive Therapeutics Provides Update on...















